Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Entropy reports sustained improvement in binge-eating study as it expands TRP-8803 trials

ENP: $0.030 +0.00% · MC: $47M

Entropy Neurodynamics reported that all six patients in the first cohort of its treatment-resistant binge-eating study maintained clinically meaningful improvement at 12 weeks, with half experiencing complete remission and weekly binge-eating episodes remaining 73% below baseline. The company also secured ethics approval for a 72-patient study across eight indications, agreed GMP manufacturing with BioCina and signed a preliminary agreement with UCSF for a potential US depression study. After quarter-end, the next study cohort began testing a shorter infusion protocol, with topline results expected by the end of 2026.

Source announcements: 2026-10-28 08:21 to 2026-10-28 08:21 Sydney time
Story updated 2026-10-28 08:37 Sydney time
SourcesQuarterly Activities Report and Appendix 4C
Comments